Gliadel Wafer en es it fr

Gliadel Wafer Brand names, Gliadel Wafer Analogs

Gliadel Wafer Brand Names Mixture

  • No information avaliable

Gliadel Wafer Chemical_Formula


Gliadel Wafer RX_link

Gliadel Wafer fda sheet

Gliadel Wafer msds (material safety sheet)

Gliadel_Wafer MSDS

Gliadel Wafer Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Gliadel Wafer Molecular Weight

214.049 g/mol

Gliadel Wafer Melting Point

31 oC

Gliadel Wafer H2O Solubility

< 0.1 g/100 mL at 18 °C

Gliadel Wafer State


Gliadel Wafer LogP


Gliadel Wafer Dosage Forms

Powder for solution; Wafer

Gliadel Wafer Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Gliadel Wafer Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Gliadel Wafer Absorption

5 to 28% bioavailability

Gliadel Wafer side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Gliadel Wafer Patient Information

No information avaliable

Gliadel Wafer Organisms Affected

Humans and other mammals